Using in vivo mouse models, the mechanisms of CD4+ T cell help have been intensively investigated. However, a mechanistic analysis of human CD4+ T cell help is largely lacking. Our goal was to elucidate the mechanisms of human CD4+ T cell help of CD8+ T cell proliferation using a novel in vitro model.
We developed a genetically engineered novel human cell-based artificial APC, aAPC/mOKT3, which expresses a membranous form of the anti-CD3 monoclonal antibody OKT3 as well as other immune accessory molecules. Without requiring the addition of allogeneic feeder cells, aAPC/mOKT3 enabled the expansion of both peripheral and tumor-infiltrating T cells, regardless of HLA-restriction. Stimulation with aAPC/mOKT3 did not expand Foxp3+ regulatory T cells, and expanded tumor infiltrating lymphocytes predominantly secreted Th1-type cytokines, interferon-γ and IL-2. In this aAPC-based system, the presence of autologous CD4+ T cells was associated with significantly improved CD8+ T cell expansion in vitro. The CD4+ T cell derived cytokines IL-2 and IL-21 were necessary but not sufficient for this effect. However, CD4+ T cell help of CD8+ T cell proliferation was partially recapitulated by both adding IL-2/IL-21 and by upregulation of IL-21 receptor on CD8+ T cells.
We have developed an in vitro model that advances our understanding of the immunobiology of human CD4+ T cell help of CD8+ T cells. Our data suggests that human CD4+ T cell help can be leveraged to expand CD8+ T cells in vitro.
Citation: Butler MO, Imataki O, Yamashita Y, Tanaka M, Ansén S, et al. (2012) Ex Vivo Expansion of Human CD8+ T Cells Using Autologous CD4+ T Cell Help. PLoS ONE 7(1): e30229. doi:10.1371/journal.pone.0030229
Editor: Derya Unutmaz, New York University, United States of America
Received: April 7, 2011; Accepted: December 13, 2011; Published: January 12, 2012
Copyright: © 2012 Butler et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the Madeleine Franchi Ovarian Research Fund (MOB), Dunkin Donuts Rising Stars Awards (MOB and NH), a grant from the Cancer Research Institute (LMN), NIH grant K22 CA129240 (NH), NIH grant R01 CA148673 (NH), and the American Society of Hematology Scholar Award (NH). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: MOB, LMN and NH have filed a patent application related to aAPC/A2. The patent application number is 10/850,294 and is entitled, "Modified Antigen-Presenting Cells." The authors confirm that this application does not alter their adherence to all PLoS ONE policies on the sharing of data and materials.
It is now well accepted that neoplastic cells are immunogenic and that tumors develop in the context of immune recognition by the host , . Tumor-associated antigens that serve as immune targets include cell lineage differentiation antigens, cancer-testes antigens, and neoantigens produced by mutations in the cancer cell's unstable genome. Mutational events can give rise to multiple immunogenic MHC class I and II restricted, non-self epitopes capable of inducing strong immune responses to the tumor , . In several maligancies, anti-tumor T cell responses, with infiltration of tumors by CD8+ T lymphocytes and local production of interferon-γ and IL-2, have been associated with improved clinical prognosis –.
Counter regulatory immune responses, however, also develop in the cancer-bearing host. Tumors subvert the immune response by secreting chemotactic factors that recruit immune suppressive elements, thereby inhibiting the function of anti-tumor effectors . Tumor infiltration by T regulatory (Treg) cells has been correlated with inferior clinical outcomes in several tumors , . These findings have led to the proposal that immune recognition of cancer involves the balancing of opposing forces: anti-tumor effectors vs. pro-tumor regulatory elements , , . In fact, a high ratio of Treg cells to CD8+ T cells within the tumor microenvironment has been associated with poorer survival , .
Adoptive T cell therapy is a promising treatment modality designed to amplify the anti-tumor immune response. Anti-tumor effectors are expanded in vitro, away from the pro-tumor milieu of the cancer bearing host, and then reinfused as a cellular therapy –. Successful approaches showing clinical activity include adoptive transfer of tumor antigen-specific T cell lines or clones that have been derived from the peripheral blood. Specificity can be achieved by stimulating antigen-specific precursor T cells or through genetic modification of expanded bulk T cells to express cloned or chimeric T cell receptor (TCR) genes –. Alternatively, the nascent, endogenous immune effector response to the tumor can be amplified by expanding tumor-infiltrating lymphocytes (TIL) in vitro. Adoptive cell transfer of in vitro activated TIL has achieved major clinical responses when patients first undergo lymphodepletion and are then given high dose IL-2 after adoptive transfer , . Lymphodepletion augments the persistence and function of transferred TIL not only by reducing or temporarily eliminating Treg cells, but also by reducing cytokine sinks that results in the accumulation of homeostatic cytokines such as IL-7 and IL-15 , .
The optimal method for generating clinically effective T cell grafts in vitro has yet to be established , . In order to achieve massive numerical expansion of T cells, current methods necessitate the use of soluble monoclonal antibodies (mAb), allogeneic feeder PBMC, EBV transformed lymphoblastoid cell lines, and/or undefined culture supernatants. Consequently, these requirements present formidable challenges and costs that prevent the widespread clinical application of this therapy. While adoptive transfer of anti-tumor CD4+ T cells can be efficacious, expansion of anti-tumor CD8+ T cells is also an important goal, particularly in light of the association between their persistence and clinical responses , –.
Insights into requirements for augmenting the expansion of both CD4+ and CD8+ T cells will help further improve methods to generate T cell grafts for adoptive therapy. CD4+ T cells help generate effective immune responses by sustaining CD8+ T cell proliferation, preventing exhaustion, and establishing long-lived functional memory . In mouse models, common γ-chain receptor cytokine and CD40 signaling can mediate CD4+ T cell help –. In clinical studies, CD4+ T cells have also been implicated in promoting the persistence and anti-tumor activity of antigen-specific CD8+ T cells in patients , . However, the mechanisms of human CD4+ T cell help are less well understood. To conduct a mechanistic analysis of human CD4+ T cell help, we developed a novel, human cell-based aAPC, aAPC/mOKT3, which induces both CD4+ and CD8+ T cell expansion without allogeneic feeder cells. The removal of allogeneic feeder cells from our T cell culture system enabled us to precisely isolate molecules mediating help of CD8+ T cell expansion that are expressed or secreted by human CD4+ T cells.
K562-based aAPC expressing membranous OKT3 induces CD3+ T cell expansion
We and others have previously reported the generation of aAPC derived from the human erythroleukemia cell line K562 –. K562 serves as an excellent platform for generating aAPC since it expresses no HLA class I or II molecules, but highly expresses adhesion molecules such as CD54 and CD58. Using K562, we developed a novel aAPC, aAPC/mOKT3, capable of expanding CD3+ T cells regardless of HLA subtype (Figure 1A, Figure S1). This aAPC was engineered to express a membranous form of the anti-CD3 mAb, OKT3, on its cell surface, thus obviating the need for adding soluble mAb to T cell cultures or loading it onto aAPC as described elsewhere , . aAPC/mOKT3 also ectopically expresses immunostimulatory molecules CD80 and CD83. We and others have shown that CD83 delivers a CD80 dependent signal that promotes lymphocyte longevity , , .
Surface expression of a transduced membranous form of anti-CD3 mAb, and transduced CD80, CD83, and endogenous HLA class I, class II, CD54, and CD58 on aAPC/mOKT3 is shown. A membranous form of anti-CD3 mAb on aAPC/mOKT3 (open) and wild type K562 (shaded) was stained using goat anti-mouse IgG (H+L). Other surface molecules were stained with each specific mAb (open) and isotype control (shaded) and analyzed by flow cytometry. Note the lack of endogenous expression of HLA class I and II on aAPC/mOKT3.
Stimulation of CD3+ T cells with aAPC/mOKT3 induces robust CD8+ T cell expansion
Peripheral CD3+ T cells expanded with aAPC/mOKT3 were phenotypically characterized after 28 days in culture (Figure 2). While the number of both CD4+ and CD8+ T cells increased, CD8+ T cells expanded substantially better than CD4+ T cells, and therefore dominated cultures from every donor tested (Figure 2A). This is in contrast to other pan T cell expansion systems such as anti-CD3/CD28 mAb-coated beads, which invariably favor the expansion CD4+ T cells over CD8+ T cells  (Figure 2B). Similar fold expansion of CD3+ T cells was obtained with the aAPC/mOKT3-based and antibody-coated bead-based expansion systems. T cells expanded using aAPC/mOKT3 displayed a central memory~effector memory phenotype (CD45RA- CD54RO+ CD62L+/-) and retained expression of receptors for IL-2, IL-7, and IL-21 (Figure 2C). CD40 ligand was highly expressed by CD4+ T cells but not CD8+ T cells. Importantly, expanded CD4+ CD25+ T cells did not express Foxp3, indicating that immunoinhibitory Treg cells did not proliferate well (Figure 2D).
(A) CD3+ T cells were stimulated twice with aAPC/mOKT3 and supplemented with IL-2 between stimulations. Fold expansion of CD3+ T cells over one month is shown for three donors. Shading shows the proportion of expanded CD4+ (white) and CD8+ (black) T cells, and percent CD8+ T cells is indicated. (B) CD3+ T cells were stimulated twice with aAPC/mOKT3 or beads (Dynabeads CD3/CD28) and supplemented with IL-2 between stimulations. Fold expansion of CD3+ T cells over one month is shown for three donors. Shading shows the proportion of expanded CD4+ (white) and CD8+ (black) T cells, and percent CD8+ T cells is indicated. (C) CD3+ T cells were expanded as described in Figure 2A. Expression of surface molecules on gated CD4+ and CD8+ T cells is shown (open). Isotype mAb staining was used as a control (shaded). (D) CD4+ CD25+ Foxp3+ Treg cells, present pre-expansion, were absent in expanded cultures. CD4+ CD25+ cells, pre- and post-expansion, were stained intracellularly with anti-Foxp3 mAb (open) and isotype control (shaded).
aAPC/mOKT3 induces unbiased CD3+ T cell expansion, preserving the repertoire for viral and tumor-associated antigens
In order to evaluate whether stimulation with aAPC/mOKT3 induced broad expansion of CD3+ T cells, TCR Vβ repertoire analysis was performed. No obvious skewing in the TCR Vβ usage of both CD4+ and CD8+ T cell populations was revealed, supporting “unbiased” T cell expansion by aAPC/mOKT3 (Figure 3A). Moreover, HLA-restricted antigen-specific CD8+ cytotoxic T lymphocytes (CTL) against viral and tumor antigens could be generated from CD3+ T cells initially expanded for four weeks using aAPC/mOKT3 (Figure 3B and 3C). The functional avidity of these tumor antigen-specific T cells was sufficient to recognize tumor targets endogenously expressing antigen, confirming that the T cell repertoire for tumor antigen recognition was preserved (Figure 3C). We also confirmed that stimulation with aAPC/mOKT3 induced the expansion of tumor-antigen specific T cells. After 28 days in culture, MART1 peptide specific CD8+ T cell expansion was 420–1,150 fold (Figure S1D).
(A) TCR Vβ subfamily analysis before and after stimulation with aAPC/mOKT3 is shown. CD3+ T cells were stimulated with aAPC/mOKT3 on days 0 and 14 and were treated with IL-2 at 300 IU/ml between stimulations. TCR Vβ usage analysis was performed on days 0, 14, 28. Data shown is on gated CD4+ and CD8+ T cells. (B, C) A2+ CD3+ T cells were stimulated twice with aAPC/mOKT3 for one month. Subsequently, CD8+ T cells were purified from expanded CD3+ T cells and further stimulated with aAPC/A2 pulsed with Flu or MART1 peptide. (B) Flu specificity was demonstrated by multimer staining (left). Functional competence was demonstrated by antigen-specific cytotoxicity (middle) and IFN-γ secretion (right). T2 cells pulsed with Flu peptide (▪) or control peptide (•) were used as targets. (C) MART1 specificity was similarly demonstrated by multimer staining (left). The HLA-A2+/MART1+ melanoma line, Malme-3M (▪), and the HLA-A2+/MART1- melanoma line, A375 (•), were used as targets in cytotoxicity (middle) and IFN-γ ELISPOT assays (right).
aAPC/mOKT3 expands functional TIL but not contaminating Treg cells
Using aAPC/mOKT3, lymphocytes derived from malignant ascites (breast and ovarian cancer) and melanoma metastases were successfully expanded without adding any allogeneic feeder cells (Figure 4A). As observed with peripheral CD3+ T cells in Figure 2A, CD8+ T cells predominantly expanded in all cultures, including those that initially contained a minimal percentage of CD8+ T cells. Importantly, Foxp3+ cells did not proliferate well (Figure 4B). As with peripheral CD3+ T cells, expanded TIL had a central memory~effector memory phenotype (CD45RA- CD62L+/-) consistent with a lack of terminal differentiation (Figure S2). Furthermore, expanded T cells highly expressed CD27 and CD28 which are associated with T cell survival and persistence in vivo -. They also secreted high quantities of IFN-γ and IL-2, while IL-4 secretion was lower and no IL-10 was produced (Figure 4C). These results demonstrate that the aAPC/mOKT3-based system can expand tumor-infiltrating CD8+ T cells in the presence of autologous CD4+ T cells, and that they display phenotypic and functional characteristics consistent with central memory~effector memory T cells.
(A) Expansion of TIL obtained from breast and ovarian cancer ascites and melanoma metastases is shown. Shading indicates the proportion of CD4+ (white) and CD8+ (black) T cells in expanded cultures. The percentage of CD8+ T cells in pre- and post-expansion cultures is shown. Note that in all samples tested, the percentage of CD8+ T cells increased even in those that initially contained a minimal percentage of CD8+ T cells. NT denotes not tested. (B) CD4+ CD25+ Foxp3+ Treg cells, present pre-expansion, were not detectable after one month of culture. CD4+ CD25+ cells were intracellularly stained with anti-Foxp3 mAb (open) and isotype control (shaded). (C) IFN-γ, IL-2, IL-4, and IL-10 secretion of expanded TIL was determined by ELISPOT assays. Cytokine secretion by TIL from the breast cancer ascites specimen prior to expansion is shown as a control. Pre-expansion samples from melanoma and ovarian cancer specimens were not studied because of low initial cell numbers.
IL-2 and IL-21 are necessary, but not sufficient, for CD4+ T cell-mediated help of CD8+ T cell expansion
Using the aAPC/mOKT3-based expansion system, we compared the expansion of CD8+ T cells in the presence or absence of CD4+ T cells. CD8+ T cells expanded much better in the presence of CD4+ T cells (Figure 5A), suggesting the presence of CD4+ T cell help for CD8+ T cells in these aAPC/mOKT3-based cultures. We tested whether this “help” was mediated by soluble factors or cell-cell contact using the transwell assay (Figure 5B). A single stimulation, without any exogenously added cytokines, expanded CD8+ T cells by an average of 40.5% better when CD4+ T cells were present but separated from CD8+ T cells by the transwell membrane (P<0.005). In co-cultures where CD4+ and CD8+ T cells were mixed, allowing for direct cell-cell contact, CD8+ T cells expanded more than in cultures where they were separated from CD4+ T cells by the transwell membrane (P<0.05). These results suggest that observed CD4+ T cell help involves both soluble factors and cell-cell contact.
(A) CD8+ T cells were stimulated twice by aAPC/mOKT3 with or without CD4+ T cells and treated with IL-2 between stimulations. Fold expansion of CD8+ T cells over 28 days is shown for 3 donors. (B) CD8+ T cells were stimulated only once by aAPC/mOKT3 with or without CD4+ T cells in transwell plates. No IL-2 or other cytokines were given. Fold expansion of CD8+ T cells over 6 days is shown for 7 donors. (C) Culture supernatants were tested for a panel of soluble factors to identify mediators of CD4+ T cell help. Relative changes in cytokines, comparing mixed vs. separate cultures, are shown. Data is representative of two donors. Absolute values for two donors are shown in Table S1. (D) Suppression of CD8+ T cell expansion in the presence of CD4+ T cells by blocking reagents is presented as percent suppression relative to control. Values indicate mean of four independent experiments; error bars show s.d. *P<0.005. (E) CD8+ T cells were stimulated twice with aAPC/mOKT3 in the presence or absence of CD4+ T cells. IL-2, IL-21, or both were added in each condition. Fold expansion of CD8+ T cells over 28 days is shown. Percent expansion was calculated by dividing the number of expanded CD8+ T cells by the number of CD8+ T cells expanded in the presence of CD4+ T cells. Values indicate mean of six independent experiments; error bars show s.d.
To identify molecules mediating the observed CD4+ T cell help, culture supernatants of CD4+/CD8+ T cell mixed and separate cultures were tested for a panel of soluble factors (Figure 5C and Table S1). Greater quantities of MIP-1α, MIP-1β, and RANTES were detected in CD4+/CD8+ T cell mixed cultures compared to separate cultures, suggesting increased production in mixed cultures. In contrast, IL-2 and IL-21, as well as IL-10, IL-17, TNF-α, and TNF-β, were detected at lower levels in mixed cultures, consistent with more consumption or less production of these cytokines.
To differentiate between “more consumption” and “less production,” CD4+/CD8+ T cell mixed cultures were stimulated in the presence of blocking reagents, and suppression of CD8+ T cell expansion was assessed (Figure 5D). Blockade of IL-2 and IL-21 resulted in a reduction of expansion by 68.8% (P<0.005) and 42.9% (P<0.005), respectively. These results indicate that the decreased levels of IL-2 and IL-21 in CD4+/CD8+ T cell mixed cultures were due to more consumption rather than less production and that these cytokines may be necessary mediators of CD4+ T cell help in this human-based in vitro system. To test whether IL-2/IL-21 could substitute for the observed CD4+ T cell help, CD8+ T cells stimulated with aAPC/mOKT3 were supplemented with IL-2, IL-21, or both (Figure 5E). CD8+ T cells did not expand without IL-2. The addition of IL-2 with or without IL-21 did not improve CD8+ T cell expansion to the level observed when cocultured with CD4+ T cells, demonstrating that IL-2 plus IL-21 are not sufficient to replace CD4+ T cell help.
Exogenous IL-2/IL-21 and upregulation of IL-21 receptor can partially recapitulate CD4+ T cell help of CD8+ T cell expansion in vitro
Interestingly, we observed that higher expression of the IL-21 receptor (IL-21R) on CD8+ T cells occurred when CD4+ T cells were present during stimulation by aAPC/mOKT3 (Figure 6A). Higher IL-21R expression on CD8+ T cells was not induced by supplementing cultures with IL-2 and IL-21 (data not shown). This prompted us to hypothesize that increased upregulation of IL-21R on CD8+ T cells is critical for the full effect of IL-21 secreted by CD4+ T cells. We constitutively expressed IL-21R on CD8+ T cells (Figure 6B, left) and stimulated them with aAPC/mOKT3 in the presence of IL-2/IL-21. In accordance with the transduction efficiency of IL-21R to 75.9%, CD8+ T cell proliferation partially increased to levels seen in the presence of CD4+ T cells (Figure 6B, right). This indicates that elevated expression of IL-21R is necessary and can partially recapitulate CD4+ T cell help for CD8+ T cell proliferation.
(A) IL-21R expression on CD8+ T cells stimulated with aAPC/mOKT3 in the presence or absence of CD4+ T cells was studied by flow cytometry. On the left, histogram plots for 1 donor is shown and, on the right, IL-21R expression on day 4 is displayed for 5 donors. (B) IL-21R expression on CD8+ T cells ectopically transduced with mock or IL-21R is shown (left). Expansion of transduced CD8+ T cells stimulated twice by aAPC/mOKT3 with or without IL-21 is compared (right). Percent expansion was calculated by dividing the number of expanded transduced CD8+ T cells by that of CD8+ T cells stimulated in the presence of CD4+ T cells. Values indicate mean of four independent experiments; error bars show s.d. *P<0.005.
A novel human cell-based aAPC expanded CD3+ T cells in vitro without the addition of allogeneic feeder PBMC. Phenotypic analysis of expanded healthy donor T cells and TIL showed, that while both CD4+ and CD8+ T cells expanded, CD8+ T cells predominated. In this model system, we demonstrated that CD8+ T cell expansion depended on the presence of CD4+ T cells, suggesting that CD4+ T cells provided help to proliferating CD8+ T cells. The CD4+ T cell secreted cytokines, IL-2 and IL-21, and the CD4+ T cell-dependent upregulation of IL-21R on CD8+ T cells were necessary for the observed CD4+ T cell help.
IL-2 and IL-21 have previously been shown to mediate CD4+ T cell help in murine in vivo studies. IL-2, one of the few effector cytokines made by naïve CD4+ T cells, expands activated T cells and is essential in the development of CD8+ T cell memory responses to pathogens . While CD8+ T cell responses during acute viral infections were relatively independent of IL-2, the development of protective CD8+ T cell memory responses required IL-2 exposure during priming –. In vivo models also indicate that IL-21 is critical for containing chronic viral infections and preventing the deletion of high affinity antiviral CD8+ T cells. IL-21 secretion by CD4+ T cells enables the generation, sustained proliferation, and maintenance of polyfunctional CD8+ T cells during chronic infection –.
Our results confirmed a role for IL-2 and IL-21 in human CD4+ T cell help. By using a standardized aAPC, we were able to single out and examine the effects of cocultured CD4+ T cells, unhindered by immunostimulatory and inhibitory factors produced by allogeneic feeder cells. Stimulation of T cells with aAPC/mOKT3 induced the secretion of cytokines and chemokines, including high levels of interferon-γ, MIP-1α, and MIP-1β. Among all the cytokines and chemokines studied, blocking experiments identified IL-2 and IL-21 as necessary for CD4+ T cell help of CD8+ T cell expansion. These cytokines alone, however, were not sufficient to replace CD4+ T cells. We showed that CD4+ T cells help by enhancing IL-21R expression on CD8+ T cells, rendering them more responsive to secreted IL-21. Taken together, the secretion of IL-2/IL-21 and the induction of IL-21R are necessary and sufficient to partially recapitulate human CD4+ T cell help of CD8+ T cell expansion in vitro.
Transwell assays showed that the CD4+ T cell dependent expansion of CD8+ T cells was also mediated by cell-cell contact factors. CD40-CD40 ligand interactions have been shown to mediate CD4+ T cell help through CD40-mediated activation of dendritic cells, which are then “licensed” to stimulate CD8+ T cells , , . CD40 ligation was also shown to increase IL-21R expression on B lymphocytes suggesting a mechanism for IL-21R upregulation on CD8+ T cells . However, we did not observe any suppression of CD8+ T cell expansion following blockade of CD40 ligand (Figure 5D) even though expanded CD4+ T cells strongly expressed CD40 ligand (Figure 2C). Furthermore, stimulation with aAPC/mOKT3 in the presence of CD40 ligation and the addition of IL-21 did not consistently enhance CD8+ T cell expansion (data not shown). Therefore, these results are in agreement with others who have shown that CD4+ T cells do not provide direct help to CD8+ T cells through CD40 ligation , . It should be noted that blocking of CD70, 4-1BB, or OX40 signaling also did not suppress the expansion of CD8+ T cells in the presence of CD4+ T cells (Figure 5D).
aAPC induced polyclonal expansion of both CD4+ and CD8+ T cells as shown by the absence of clonal skewing of the TCR Vβ repertoire. The ability to further expand antigen-specific T cells capable of killing tumor targets indicated that the TCR repertoire for highly avid T cells was preserved. Also, expanded TIL secreted higher amounts of Th1 cytokines, IFN-γ and IL-2, which are associated with anti-tumor immunity. While aAPC/mOKT3 induced substantial expansion of CD8+ T cells in the presence of CD4+ T cell help, terminal effector T cell differentiation did not occur, as demonstrated by the central memory~effector memory phenotype (CD45RA- CD45RO+ CD62L+/-). Retention of CD62L expression would enable homing to lymph nodes, where encounter with antigen presented by professional APC could augment immune responses . CD27, which is down-regulated in late stage effector T cells, was also highly expressed. CD27 expression by in vitro expanded TIL and T cell clones has been associated with persistence and clinical responses after adoptive transfer , , , .
We also found that expanded T cells were not contaminated by cells with the CD4+ CD25+ Foxp3+ Treg phenotype even when CD4+ CD25+ Foxp3+ T cells were present prior to stimulation. We previously found that K562-based aAPC expressing HLA-DR molecules did not expand Foxp3+ cells even though aAPC itself produces modest amounts of the Treg cell growth factor TGF-β . We previously reported that aAPC also secretes IL-6 . It is possible that IL-6, secreted by aAPC, might interfere with Foxp3+ Treg cell expansion , .
Adoptive transfer of in vitro expanded T cells has led to clinically significant anti-tumor responses in patients . By leveraging autologous CD4+ T cell help, aAPC/mOKT3 eliminates the use allogeneic feeder cells for T cell expansion, potentially increasing the availability of adoptive therapy as a cancer treatment. We previously reported the development of K562-based aAPCs dedicated to the expansion of HLA-restricted antigen-specific CD4+ and CD8+ T cells , . Antigen-specific CD4+ and CD8+ T cells expanded in vitro with these aAPC had a central memory~effector memory phenotype (CD45RA- CD62L+/-) and possessed surprisingly prolonged in vitro longevity without feeder cells or cloning. In a recent clinical trial, HLA-A2-restricted MART1 peptide-specific CD8+ T cells generated in vitro with aAPC were infused to advanced melanoma patients . Without lymphodepletion or IL-2 administration, transferred T cells could persist for >16 months, established anti-tumor immunological memory in vivo, trafficked to tumor, and induced clinical responses. aAPC/mOKT3 extends the K562 platform to the stimulation of T cells regardless of HLA subtype. The aAPC/mOKT3-based T cell expansion system facilitates the understanding of mechanisms for human CD4+ T cell help and provides a novel strategy to expand T cells for in vitro and in vivo uses.
Materials and Methods
All specimens and clinical data were collected under protocols approved by the Institutional Review Board at the Dana-Farber Cancer Institute (DFCI). All patients provided written informed consent for the collection of samples and subsequent analysis.
cDNAs and cell lines
cDNAs encoding the heavy and light chains for a membranous form of anti-CD3 mAb (OKT3, mIgG2a) were cloned from hybridoma cells (ATCC, VA). HLA null K562 transduced with CD80 and CD83 has been described previously , . CD80+ CD83+ K562 cells were retrovirally transduced with the heavy and light chains of a membranous form of anti-CD3 mAb. After drug selection, anti-CD3 mAb expressing cells were isolated by magnetic bead guided sorting (Miltenyi Biotec, CA). High expression of a membranous form of anti-CD3 mAb on the cell surface was confirmed by flow cytometry. The parental cell line K562 lacks the endogenous expression of any HLA molecule, but does endogenously express the adhesion molecules CD54 and CD58.
Retrovirus supernatants expressing IL-21R was harvested from PG13 cells. Fresh CD8+ T cells purified from healthy donors were first activated with anti-CD3 (0.75 µg/ml) and anti-CD28 (1 µg/ml) mAbs (Fitzgerald Industries International, MA) for two days. Pre-activated T cells were infected with IL-21R or mock retrovirus supernatants every 24 hr at an MOI of 10 for 10 days and treated with 50 IU/ml IL-2 between infections. Following the assessment of IL-21R expression by flow cytometry analysis, infected T cells were stimulated with aAPC/mOKT3.
T2, A375, and Malme-3M cell lines were obtained from ATCC as described elsewhere .
T cell expansion
Healthy donor PBMC were obtained by leukapheresis performed at the DFCI Kraft Family Blood Donor Center. Cells were isolated by Ficoll-Hypaque density gradient centrifugation and CD3+, CD4+, or CD8+ T cells were purified by negative selection via MACS sorting according to the manufacturer's protocol (Miltenyi Biotec, CA). TIL samples were processed by centrifugation of malignant ascites or mechanical and enzymatic digestion of melanoma metastases with collagenase as previously described . CD3+ TIL were obtained by positive or negative selection via MACS sorting (Miltenyi Biotec, CA). aAPC/mOKT3 cells were irradiated (200 Gy) and added to purified T cells at a T cell to aAPC ratio of 20:1 unless otherwise noted. Dynabeads CD3/CD28 (Invitrogen, CA) were used as stimulators according to the manufacturer's instruction at a T cell to bead ratio of 1:3. Expanding T cells were cultured in RPMI 1640 containing 10% human AB sera and gentamycin (Invitrogen, CA), and between stimulations, unless otherwise noted, 300 IU/ml IL-2 (Prometheus, CA) was added every 3-4 days. In the absence of CD4+ T cells, CD8+ T cells expanded only in the presence of IL-2. Where indicated, 50 ng/ml IL-21 (Peprotech, NJ) was added every 3-4 days. Unless otherwise noted, T cells were restimulated every two weeks. Expanded cells were characterized two weeks after the second stimulation. Cell viability was >90% by trypan blue exclusion.
To test whether antigen-specific cultures can be generated from CD3+ T cells polyclonally expanded with aAPC/mOKT3, CD3+ T cells derived from HLA-A*0201 (A2)+ donors were initially stimulated and expanded with aAPC/mOKT3 for one month. Subsequently, CD8+ T cells were purified and further stimulated with Flu or MART1 peptide-pulsed aAPC/A2 as previously described , .
Analysis of cultured T cells
Flow cytometry analysis was performed using mAbs for the following antigens: CD4, CD8, CD25, CD28, CD56, CD62L, and IL-2Rβ (Coulter, CA); CD40 ligand, CD80, IL-7Rα, OX40, OX40 ligand, and 4-1BB (BD Biosciences, CA); CD27, CD45RA, CD45RO and CD83 (Invitrogen, CA); CCR4 and CCR7 (R&D Systems, MN); ICOS, NKG2D, and PD-1 (eBioscience, CA); CD38, Foxp3, HLA-DR, and 4-1BB ligand (Biolegend, CA); CD40 and CD70 (Ancell, MN); IL-21R (R&D Systems, MN; or BD Biosciences, CA). Goat anti-mouse IgG (H+L) Fab (Jackson ImmunoResearch, PA) was used to detect surface expression of murine Ig. Assessment of TCR Vβ subfamily usage was performed using TCR Vβ mAbs (Beta Mark, Coulter, CA).
To assess the production/consumption of soluble factors in T cell cultures, purified CD4+, CD8+, or a 1:1 mixture of CD4+ and CD8+ T cells were stimulated with irradiated aAPC/mOKT3 for 72 hours and supernatants were measured for: GM-CSF, IFN-γ, IL-2, IL-4, IL-10, IL-12, IL-15, IL-17, MIP-1α, MIP-1β, RANTES, TNF-α, TNF-β, and TRAIL (R&D Systems, MN); IL-7 (Diaclone/Cell Sciences, MA); IL-18 (Medical & Biological Laboratories, Japan); and IFN-α (PBL Biomedical Laboratories, NJ). IL-21 (eBiosciences, CA) was measured at 48-hours. Relative changes in cytokines resulting from mixed cultures of CD4+ and CD8+ T cells vs. separate CD4+ and CD8+ T cell cultures were determined by the following formula: (x-y)/y, where x = cytokine secreted by CD4+ and CD8+ T cell mixed co-cultures and y is the average of cytokine produced in separately stimulated CD4+ and CD8+ T cell cultures.
IFN-γ ELISPOT and standard chromium release assays were performed as described elsewhere , . IL-2, IL-4 and IL-10 ELISPOT assays were performed according to the manufacturer's protocol (R&D Systems, MN).
Transwell and blocking assays
Transwell assays were performed by placing purified CD4+, CD8+, or a mixture of CD4+ and CD8+ T cells into Millicell-24 plate chambers (Millipore) which were separated by a 0.4 µm filter allowing free movement of soluble factors but not cells. T cells were stimulated once with aAPC/mOKT3 in the absence of exogenous cytokines. Six days later, expansion of CD8+ T cells was determined.
Blocking assays were performed in 96-well round bottomed plates where CD4+ and CD8+ T cells were combined 1:1 and then stimulated with irradiated mOKT3/aAPC in the presence of blocking reagents. Blocking mAbs used recognized IL-2, IL-10, IL-15, IL-17R, MIP-1α, MIP-1β, OX40 ligand, RANTES, TNFα, and TNFβ (R&D Systems, MN); 4-1BB (Neomarkers, CA); CD40 ligand (Biolegend, CA); and CD70 (Ancell, MN). IL-21 was blocked using recombinant human IL-21R subunit/Fc chimeric protein (R&D Systems, MN) as previously described . Six days later, CD8+ T cell expansion was determined.
Data analysis was performed using the paired, one-sided Student's t-test where P<0.05 was considered to be statistically significant.
K562-based aAPC/mOKT3, expressing a membranous form of anti-CD3 mAb, stimulates CD3+ T cell expansion. (A) CD3+ T cells were stimulated twice with aAPC/mOKT3 and supplemented with IL-2 at the following concentrations: 10 IU/ml (gray), 300 IU/ml (white) and 6,000 IU/ml (black). Fold expansion over 28 days is demonstrated. Without IL-2 addition, T cell expansion over the 28-day culture period was minimal. Data for three separate donors is shown. (B) CD3+ T cells were stimulated twice with aAPC/mOKT3 at the indicated aAPC: T cell ratios. Cultures were supplemented with IL-2 (300 IU/ml) between stimulations. Fold expansion of CD3+ T cells over one month is shown for two donors. (C) Phenotype of fresh healthy donor CD3+ T cells prior to stimulation is depicted to compare with the T cells shown in Figure 2C which were expanded with aAPC/mOKT3. Expression of surface molecules on gated CD4+ and CD8+ T cells is shown (open). Isotype mAb staining was used as a control (shaded). (D) HLA-A2+ healthy donor CD8+ T cells were stimulated with MART1 peptide-pulsed aAPC/A2 as previously described , . MART1 specific T cells were then stimulated twice with aAPC/mOKT3 in the presence of autologous CD4+ T cells. Fold expansion of MART1 T cells over one month is shown for three donors.
TIL expanded with aAPC/mOKT3 express CD27 and CD28 and have a central memory~effector memory phenotype. CD3+ T cells from malignant ovarian ascites were stimulated twice with aAPC/mOKT3, and cultures were supplemented with IL-2 at 300 IU/ml. (A) Fresh, unstimulated TIL and (B) aAPC/mOKT3 expanded TIL were stained with indicated mAb (open) and isotype control (shaded). TIL were analyzed after a one month expansion. Data depicted is on gated CD4+ and CD8+ T cells.
Soluble factors in T cell cultures stimulated with aAPC/mOKT3. Concentrations of soluble factors (pg/ml) in supernatants of CD4+ separate, or CD8+ separate, and CD4+ and CD8+ mixed T cell cultures stimulated by aAPC/mOKT3 were measured by ELISA. aPercent change was calculated as detailed in Methods. bnot applicable. Data from two different donors is depicted.
Conceived and designed the experiments: MOB LMN NH. Performed the experiments: MOB OI MT SA AB GM MIM MMM APM NH. Analyzed the data: MOB LMN NH. Contributed reagents/materials/analysis tools: MOB OI YY MT SA HM LMN NH. Wrote the paper: MOB LMN NH.
- 1. Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21: 137–148.
- 2. Pellegrini M, Mak TW, Ohashi PS (2010) Fighting cancers from within: augmenting tumor immunity with cytokine therapy. Trends Pharmacol Sci 31: 356–363.
- 3. Segal NH, Parsons DW, Peggs KS, Velculescu V, Kinzler KW, et al. (2008) Epitope landscape in breast and colorectal cancer. Cancer Res 68: 889–892.
- 4. Parmiani G, De Filippo A, Novellino L, Castelli C (2007) Unique human tumor antigens: immunobiology and use in clinical trials. J Immunol 178: 1975–1979.
- 5. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, et al. (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348: 203–213.
- 6. Marth C, Fiegl H, Zeimet AG, Muller-Holzner E, Deibl M, et al. (2004) Interferon-gamma expression is an independent prognostic factor in ovarian cancer. Am J Obstet Gynecol 191: 1598–1605.
- 7. Kusuda T, Shigemasa K, Arihiro K, Fujii T, Nagai N, et al. (2005) Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer. Oncol Rep 13: 1153–1158.
- 8. Mihm MC Jr, Clemente CG, Cascinelli N (1996) Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest 74: 43–47.
- 9. Mantovani A, Romero P, Palucka AK, Marincola FM (2008) Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 371: 771–783.
- 10. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, et al. (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10: 942–949.
- 11. Kobayashi N, Hiraoka N, Yamagami W, Ojima H, Kanai Y, et al. (2007) FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 13: 902–911.
- 12. Wilke CM, Wu K, Zhao E, Wang G, Zou W (2010) Prognostic significance of regulatory T cells in tumor. Int J Cancer 127: 748–758.
- 13. Shimizu J, Yamazaki S, Sakaguchi S (1999) Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163: 5211–5218.
- 14. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, et al. (2005) Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 102: 18538–18543.
- 15. Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, et al. (2007) Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 25: 2586–2593.
- 16. Bollard CM, Gottschalk S, Leen AM, Weiss H, Straathof KC, et al. (2007) Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 110: 2838–2845.
- 17. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, et al. (2008) Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26: 5233–5239.
- 18. Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, et al. (2008) Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 358: 2698–2703.
- 19. Mackensen A, Meidenbauer N, Vogl S, Laumer M, Berger J, et al. (2006) Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J Clin Oncol 24: 5060–5069.
- 20. Peggs KS, Verfuerth S, Pizzey A, Khan N, Guiver M, et al. (2003) Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 362: 1375–1377.
- 21. Berger C, Turtle CJ, Jensen MC, Riddell SR (2009) Adoptive transfer of virus-specific and tumor-specific T cell immunity. Curr Opin Immunol 21: 224–232.
- 22. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, et al. (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314: 126–129.
- 23. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, et al. (2008) Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 14: 1264–1270.
- 24. Till BG, Jensen MC, Wang J, Chen EY, Wood BL, et al. (2008) Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 112: 2261–2271.
- 25. Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M, et al. (2006) Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 24: e20–22.
- 26. Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, et al. (2006) A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 12: 6106–6115.
- 27. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, et al. (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23: 2346–2357.
- 28. Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, et al. (2005) Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 202: 907–912.
- 29. Klebanoff CA, Khong HT, Antony PA, Palmer DC, Restifo NP (2005) Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol 26: 111–117.
- 30. Rosenberg SA, Dudley ME (2009) Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 21: 233–240.
- 31. Zhou J, Dudley ME, Rosenberg SA, Robbins PF (2005) Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. J Immunother 28: 53–62.
- 32. Robbins PF, Dudley ME, Wunderlich J, El-Gamil M, Li YF, et al. (2004) Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol 173: 7125–7130.
- 33. Muranski P, Restifo NP (2009) Adoptive immunotherapy of cancer using CD4(+) T cells. Curr Opin Immunol 21: 200–208.
- 34. Rochman Y, Spolski R, Leonard WJ (2009) New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol 9: 480–490.
- 35. Wilson EB, Livingstone AM (2008) Cutting edge: CD4+ T cell-derived IL-2 is essential for help-dependent primary CD8+ T cell responses. J Immunol 181: 7445–7448.
- 36. Bachmann MF, Wolint P, Walton S, Schwarz K, Oxenius A (2007) Differential role of IL-2R signaling for CD8+ T cell responses in acute and chronic viral infections. Eur J Immunol 37: 1502–1512.
- 37. Williams MA, Tyznik AJ, Bevan MJ (2006) Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. Nature 441: 890–893.
- 38. Bevan MJ (2004) Helping the CD8(+) T-cell response. Nat Rev Immunol 4: 595–602.
- 39. Elsaesser H, Sauer K, Brooks DG (2009) IL-21 is required to control chronic viral infection. Science 324: 1569–1572.
- 40. Yi JS, Du M, Zajac AJ (2009) A vital role for interleukin-21 in the control of a chronic viral infection. Science 324: 1572–1576.
- 41. Frohlich A, Kisielow J, Schmitz I, Freigang S, Shamshiev AT, et al. (2009) IL-21R on T cells is critical for sustained functionality and control of chronic viral infection. Science 324: 1576–1580.
- 42. Oh S, Perera LP, Terabe M, Ni L, Waldmann TA, et al. (2008) IL-15 as a mediator of CD4+ help for CD8+ T cell longevity and avoidance of TRAIL-mediated apoptosis. Proc Natl Acad Sci U S A 105: 5201–5206.
- 43. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ (1998) T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393: 480–483.
- 44. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, et al. (1998) Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393: 478–480.
- 45. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, et al. (1995) Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333: 1038–1044.
- 46. Haque T, Wilkie GM, Jones MM, Higgins CD, Urquhart G, et al. (2007) Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 110: 1123–1131.
- 47. Butler MO, Lee JS, Ansen S, Neuberg D, Hodi FS, et al. (2007) Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell. Clin Cancer Res 13: 1857–1867.
- 48. Butler MO, Ansen S, Tanaka M, Imataki O, Berezovskaya A, et al. (2010) A panel of human cell-based artificial APC enables the expansion of long-lived antigen-specific CD4+ T cells restricted by prevalent HLA-DR alleles. Int Immunol 22: 863–873.
- 49. Numbenjapon T, Serrano LM, Singh H, Kowolik CM, Olivares S, et al. (2006) Characterization of an artificial antigen-presenting cell to propagate cytolytic CD19-specific T cells. Leukemia 20: 1889–1892.
- 50. Suhoski MM, Golovina TN, Aqui NA, Tai VC, Varela-Rohena A, et al. (2007) Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. Mol Ther 15: 981–988.
- 51. Maus MV, Thomas AK, Leonard DG, Allman D, Addya K, et al. (2002) Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol 20: 143–148.
- 52. Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA (2003) Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 26: 332–342.
- 53. Hirano N, Butler MO, Xia Z, Ansen S, von Bergwelt-Baildon MS, et al. (2006) Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity. Blood 107: 1528–1536.
- 54. Prazma CM, Yazawa N, Fujimoto Y, Fujimoto M, Tedder TF (2007) CD83 expression is a sensitive marker of activation required for B cell and CD4+ T cell longevity in vivo. J Immunol 179: 4550–4562.
- 55. Levine BL, Bernstein WB, Connors M, Craighead N, Lindsten T, et al. (1997) Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells. J Immunol 159: 5921–5930.
- 56. Powell DJ Jr, Dudley ME, Robbins PF, Rosenberg SA (2005) Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 105: 241–250.
- 57. Ochsenbein AF, Riddell SR, Brown M, Corey L, Baerlocher GM, et al. (2004) CD27 expression promotes long-term survival of functional effector-memory CD8+ cytotoxic T lymphocytes in HIV-infected patients. J Exp Med 200: 1407–1417.
- 58. Zhou J, Shen X, Huang J, Hodes RJ, Rosenberg SA, et al. (2005) Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol 175: 7046–7052.
- 59. Huang J, Kerstann KW, Ahmadzadeh M, Li YF, El-Gamil M, et al. (2006) Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy. J Immunol 176: 7726–7735.
- 60. Waldmann TA (2006) The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 6: 595–601.
- 61. Ridge JP, Di Rosa F, Matzinger P (1998) A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393: 474–478.
- 62. de Totero D, Meazza R, Zupo S, Cutrona G, Matis S, et al. (2006) Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates proapoptotic signals in chronic lymphocytic leukemia B cells. Blood 107: 3708–3715.
- 63. Lee BO, Hartson L, Randall TD (2003) CD40-deficient, influenza-specific CD8 memory T cells develop and function normally in a CD40-sufficient environment. J Exp Med 198: 1759–1764.
- 64. Sun JC, Bevan MJ (2004) Cutting edge: long-lived CD8 memory and protective immunity in the absence of CD40 expression on CD8 T cells. J Immunol 172: 3385–3389.
- 65. Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, et al. (2005) Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8(+) T cells. J Clin Invest 115: 1616–1626.
- 66. Huang J, Khong HT, Dudley ME, El-Gamil M, Li YF, et al. (2005) Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J Immunother 28: 258–267.
- 67. Korn T, Bettelli E, Oukka M, Kuchroo VK (2009) IL-17 and Th17 Cells. Annu Rev Immunol 27: 485–517.
- 68. Li MO, Flavell RA (2008) Contextual regulation of inflammation: a duet by transforming growth factor-beta and interleukin-10. Immunity 28: 468–476.
- 69. Butler M, Friedlander P, Mooney M, Drury L, Metzler M, et al. (2009) Establishing CD8+ T Cell Immunity by Adoptive Transfer of Autologous, IL-15 Expanded, Anti-Tumor CTL with a Central/Effector Memory Phenotype Can Induce Objective Clinical Responses. Blood (ASH Annual Meeting Abstracts) 114: 782-.
- 70. Soiffer R, Lynch T, Mihm M, Jung K, Rhuda C, et al. (1998) Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci U S A 95: 13141–13146.
- 71. Andersson AK, Feldmann M, Brennan FM (2008) Neutralizing IL-21 and IL-15 inhibits pro-inflammatory cytokine production in rheumatoid arthritis. Scand J Immunol 68: 103–111.